EP Patent

EP3675827A1 — Formulations of pimavanserin

Assigned to Acadia Pharmaceuticals Inc · Expires 2020-07-08 · 6y expired

What this patent protects

Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.

USPTO Abstract

Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.

Drugs covered by this patent

Patent Metadata

Patent number
EP3675827A1
Jurisdiction
EP
Classification
—
Expires
2020-07-08
Drug substance claim
No
Drug product claim
No
Assignee
Acadia Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.